Sierra Oncology, Inc.
(NASDAQ GM: SRRA)
Rigrodsky Law, P.A. is investigating Sierra Oncology, Inc. (“Sierra”) regarding possible breaches of fiduciary duties and other violations of law related to Sierra’s agreement to be acquired by GlaxoSmithKline plc. Under the terms of the agreement, Sierra’s shareholders will receive $55.00 in cash for each share of Sierra common stock they own.